UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
AlloVir, Inc.
| (Address of principal executive offices, including zip code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trade Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On February 9, 2024, AlloVir, Inc. (“AlloVir”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of AlloVir’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, AlloVir is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
The notice from Nasdaq has no immediate effect on the listing of AlloVir’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the symbol “ALVR”.
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), AlloVir has automatically been afforded a 180-calendar day period, or until August 7, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard will be met if the closing bid price of AlloVir’s common stock is at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. If AlloVir is not in compliance by August 7, 2024, AlloVir may be afforded a second 180-calendar day period to regain compliance if it meets certain requirements.
AlloVir intends to monitor the closing bid price of its common stock and is currently evaluating its options for regaining compliance, which could include a reverse stock split of AlloVir’s common stock.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AlloVir, Inc. | ||||||
| Date: February 12, 2024 | By: | /s/ Edward Miller | ||||
| Name: | Edward Miller | |||||
| Title: | General Counsel | |||||